MannKind Corporation to Hold Investor Conference Call on February 3, 2016
January 27 2016 - 9:00AM
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD)
will host a conference call to discuss Company developments at 5:00
PM (Eastern Time) on February 3, 2016.
Presenting from the Company will be its Chief
Executive Officer, Matthew Pfeffer and Chief Medical Officer,
Raymond Urbanski.
To view and listen to the webcast, visit
MannKind’s website at http://www.mannkindcorp.com and click on the
“MannKind 2/3/16 Conference Call” link in the Webcast section of
News & Events. To participate in the live call by telephone,
please dial (888) 771-4371 or (847) 585-4405 and use the
participant passcode: 41729996. A telephone replay of the call will
be accessible for approximately 14 days following completion of the
call by dialing (888) 843-7419 or (630) 652-3042 and use the
participant passcode: 4172 9996#. A replay will also be available
on MannKind's website for 14 days.
As with past calls, the Company will take live
questions from covering analysts. However, departing slightly
from past practice for this call, stockholders who wish
to submit questions in advance of the call should email them
to ir@mannkindcorp.com.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD)
focuses on the discovery and development of therapeutic products
for patients with diseases such as diabetes. MannKind
maintains a website at http://www.mannkindcorp.com to which
MannKind regularly posts copies of its press releases as well as
additional information about MannKind. Interested persons can
subscribe on the MannKind website to e-mail alerts that are sent
automatically when MannKind issues press releases, files its
reports with the Securities and Exchange Commission or posts
certain other information to the website.
Company Contact:Matthew J. PfefferChief
Executive Officer661-775-5300mpfeffer@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024